Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232790 · ClinicalTrials.gov registry record · NA
A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT01232790 is a NA study that has completed, run by Yale University. The registered enrollment target is 28 participants.
The verdict
NCT01232790, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizophrenia.
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT N-Acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232790
The ClinicalTrials.gov registry entry for NCT01232790 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01232790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01232790 about?
NCT01232790 is a clinical study titled "A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia". The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizophrenia.
What is the current status of trial NCT01232790?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2010-02. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01232790?
The interventions under investigation include: Placebo (DRUG), N-Acetylcysteine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01232790?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.